Tuberculosis Molecular Bacterial Load Assay reveals early delayed bacterial killing in patients with relapse

Nyanda Elias  Ntinginya; Abishek  Bakuli; Daniel  Mapamba; Wilber Sabiiti; Gibson  Kibiki; Lilian Tina  Minja; Davis  Kuchaka; Klaus  Reither; Patrick  Phillips; Martin J  Boeree; Stephen Henry Gillespie; Michael  Hoelscher; Norbert  Heinrich; PanACEA Consortium

doi:10.1093/cid/ciac445

Tuberculosis Molecular Bacterial Load Assay reveals early delayed bacterial killing in patients with relapse

Nyanda Elias Ntinginya
, Abishek Bakuli
, Daniel Mapamba
, Wilber Sabiiti
, Gibson Kibiki
, Lilian Tina Minja
, Davis Kuchaka
, Klaus Reither
, Patrick Phillips
, Martin J Boeree
, Stephen Henry Gillespie
, Michael Hoelscher
, Norbert Heinrich^*
, PanACEA Consortium

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Bacterial killing in patients with tuberculosis (TB) relapse was compared to that in patients achieving cure, measured by TB molecular bacterial load assay (TB-MBLA) or mycobacteria growth indicator tube (MGIT) time to positivity (TTP). TB-MBLA in 4 relapsed patients was significantly different compared to 132 cured patients after 2 weeks of treatment; MGIT TTP showed a significant difference from week 8.

Original language	English
Article number	ciac445
Pages (from-to)	e990-e994
Number of pages	5
Journal	Clinical Infectious Diseases
Volume	76
Issue number	3
Early online date	19 Jun 2022
DOIs	https://doi.org/10.1093/cid/ciac445
Publication status	Published - 1 Feb 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Tuberculosis
Biomarker
Relapse
Clinical trial

Access to Document

10.1093/cid/ciac445Licence: CC BY-NC-ND

Ntinginya-2022-TB-MLA-assay-reveals-ClinInfectDis-ciac445-CC
Copyright © The Author(s) 2022. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact [email protected].
Final published version, 444 KBLicence: CC BY-NC-ND

Handle.net

Persistent link to portal record

Cite this

Ntinginya, N. E., Bakuli, A., Mapamba, D., Sabiiti, W., Kibiki, G., Minja, L. T., Kuchaka, D., Reither, K., Phillips, P., Boeree, M. J., Gillespie, S. H., Hoelscher, M., Heinrich, N., & PanACEA Consortium (2023). Tuberculosis Molecular Bacterial Load Assay reveals early delayed bacterial killing in patients with relapse. Clinical Infectious Diseases, 76(3), e990-e994. Article ciac445. https://doi.org/10.1093/cid/ciac445

@article{14f769175a5d42709fdfb0106da8eb40,

title = "Tuberculosis Molecular Bacterial Load Assay reveals early delayed bacterial killing in patients with relapse",

abstract = "Bacterial killing in patients with tuberculosis (TB) relapse was compared to that in patients achieving cure, measured by TB molecular bacterial load assay (TB-MBLA) or mycobacteria growth indicator tube (MGIT) time to positivity (TTP). TB-MBLA in 4 relapsed patients was significantly different compared to 132 cured patients after 2 weeks of treatment; MGIT TTP showed a significant difference from week 8.",

keywords = "Tuberculosis, Biomarker, Relapse, Clinical trial",

author = "Ntinginya, \{Nyanda Elias\} and Abishek Bakuli and Daniel Mapamba and Wilber Sabiiti and Gibson Kibiki and Minja, \{Lilian Tina\} and Davis Kuchaka and Klaus Reither and Patrick Phillips and Boeree, \{Martin J\} and Gillespie, \{Stephen Henry\} and Michael Hoelscher and Norbert Heinrich and \{PanACEA Consortium\}",

note = "Funding: this work was supported by several funding agencies. The PanACEA MAMS study was funded by the European and Developing Countries Clinical Trials Partnership (EDCTP1); Grant No. IP.2007.32011.013, IP.2007.32011.012, and IP.2007.32011.011 as well as by the German Ministry of Education and Research (01KA0901). This analysis was funded by the German Center for Infection Research (DZIF); grant no. 02.702.",

year = "2023",

month = feb,

day = "1",

doi = "10.1093/cid/ciac445",

language = "English",

volume = "76",

pages = "e990--e994",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "3",

}

Ntinginya, NE, Bakuli, A, Mapamba, D, Sabiiti, W, Kibiki, G, Minja, LT, Kuchaka, D, Reither, K, Phillips, P, Boeree, MJ, Gillespie, SH, Hoelscher, M, Heinrich, N & PanACEA Consortium 2023, 'Tuberculosis Molecular Bacterial Load Assay reveals early delayed bacterial killing in patients with relapse', Clinical Infectious Diseases, vol. 76, no. 3, ciac445, pp. e990-e994. https://doi.org/10.1093/cid/ciac445

TY - JOUR

T1 - Tuberculosis Molecular Bacterial Load Assay reveals early delayed bacterial killing in patients with relapse

AU - Ntinginya, Nyanda Elias

AU - Bakuli, Abishek

AU - Mapamba, Daniel

AU - Sabiiti, Wilber

AU - Kibiki, Gibson

AU - Minja, Lilian Tina

AU - Kuchaka, Davis

AU - Reither, Klaus

AU - Phillips, Patrick

AU - Boeree, Martin J

AU - Gillespie, Stephen Henry

AU - Hoelscher, Michael

AU - Heinrich, Norbert

AU - PanACEA Consortium

N1 - Funding: this work was supported by several funding agencies. The PanACEA MAMS study was funded by the European and Developing Countries Clinical Trials Partnership (EDCTP1); Grant No. IP.2007.32011.013, IP.2007.32011.012, and IP.2007.32011.011 as well as by the German Ministry of Education and Research (01KA0901). This analysis was funded by the German Center for Infection Research (DZIF); grant no. 02.702.

PY - 2023/2/1

Y1 - 2023/2/1

N2 - Bacterial killing in patients with tuberculosis (TB) relapse was compared to that in patients achieving cure, measured by TB molecular bacterial load assay (TB-MBLA) or mycobacteria growth indicator tube (MGIT) time to positivity (TTP). TB-MBLA in 4 relapsed patients was significantly different compared to 132 cured patients after 2 weeks of treatment; MGIT TTP showed a significant difference from week 8.

AB - Bacterial killing in patients with tuberculosis (TB) relapse was compared to that in patients achieving cure, measured by TB molecular bacterial load assay (TB-MBLA) or mycobacteria growth indicator tube (MGIT) time to positivity (TTP). TB-MBLA in 4 relapsed patients was significantly different compared to 132 cured patients after 2 weeks of treatment; MGIT TTP showed a significant difference from week 8.

KW - Tuberculosis

KW - Biomarker

KW - Relapse

KW - Clinical trial

U2 - 10.1093/cid/ciac445

DO - 10.1093/cid/ciac445

M3 - Article

SN - 1058-4838

VL - 76

SP - e990-e994

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 3

M1 - ciac445

ER -

Tuberculosis Molecular Bacterial Load Assay reveals early delayed bacterial killing in patients with relapse

Abstract

UN SDGs

Keywords

Access to Document

Handle.net

Fingerprint

Cite this